Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

64.13 -2.02 (-3.06%)
Streaming Delayed Price Updated: 2:09 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,734,586
Open 64.40
Bid (Size) 64.12 (5)
Ask (Size) 64.14 (4)
Prev. Close 66.15
Today's Range 63.13 - 64.70
52wk Range 57.00 - 148.15
Shares Outstanding N/A
Dividend Yield 3.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Exposures Political
Why Novo Nordisk Stock Just Slipped
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price. 
Via The Motley Fool

Performance

YTD
-26.7%
-26.7%
1 Month
-0.6%
-0.6%
3 Month
-18.7%
-18.7%
6 Month
-39.1%
-39.1%
1 Year
-52.4%
-52.4%

More News

Read More
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Via Investor's Business Daily
Exposures Product Safety
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Via Benzinga
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
Via Stocktwits
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Via The Motley Fool
Is It Time to Buy the Dip in Novo Nordisk Stock?
Via MarketBeat
Topics Government
Exposures Political Product Safety
Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds
Via Benzinga
Topics Economy
Exposures Economy
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs
Via Benzinga
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing
Via Investor's Business Daily
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled
Via Stocktwits
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
Exposures Political
Is the Fed on the Right Track?
Via The Motley Fool
Topics Economy World Trade
Exposures Interest Rates Tariff
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
Big News! U.S. and China Trade Deal Shakes Up Markets
Via The Motley Fool
Topics World Trade
Exposures Tariff
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
Via Benzinga
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'
Via Benzinga
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Via Benzinga
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Via Stocktwits
Topics Government
Exposures Political
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Via Benzinga
Topics Government
Exposures Political
Deal Dispatch: Nestlé, Coinbase, OpenAI Lead Diverse M&A Lineup As WeightWatchers Goes Bankrupt
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
Via Benzinga
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Via Benzinga
Topics ETFs Government
Exposures Political
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
Via Chartmill

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 64.13
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 05/16/25 02:09 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.